Background: In order to increase eradication rates, vonoprazan, a novel potassium-
choice for H. pylori eradication. 4, 8, 9 However, the treatment regimen is still a concern in light of the decreasing eradication rates owing to the increased antibiotic resistance of H. pylori.
10-14
Recently, vonoprazan, a novel potassium-competitive acid blocker, has been used in H. pylori eradication therapy in order to increase the eradication rate. 15 Similarly to PPIs, vonoprazan inhibits gastric hydrogen/potassium-adenosine triphosphatase. 16 However, it has a more rapid and sustained acid-inhibitory effect compared to PPIs. 17 Therefore, the H. pylori eradication rate has been expected to improve with the use of the vonoprazan-based eradication regimen. 18 In recent years, studies comparing the eradication rates between the vonoprazan-based and PPI-based triple therapies have been reported in many centres in Japan. 15, [19] [20] [21] [22] [23] [24] [25] [26] [27] At this time, summarising the results of the vonoprazan-based triple therapy in terms of eradication efficacy may help clinicians to better understand the benefit of vonoprazan in the treatment of H. pylori infection. Hence, we performed a systematic review and meta-analysis of existing comparative studies that investigated the H. pylori eradication rates of both the vonoprazan-based and PPI-based triple therapies.
2 | ME TH ODS
| Search strategy
We searched for all relevant studies published between January 1990 and January 2017 that examined the H. pylori eradication rates of the vonoprazan-based and PPI-based triple therapies, using MED- [pylori] ). The detailed search strategies in each database are shown in Appendix S1. In addition, we examined the references of the screened articles to identify additional studies. All human studies published in English were considered, and the date of our most recent search update was March 6, 2017.
| Study selection
In the first stage of study selection, we excluded irrelevant articles by examining the titles and abstracts of the papers returned by our keyword search. Next, we screened the full-text of all selected studies according to our inclusion and exclusion criteria. The inclusion criteria were as follows: (1) patients-the study involved patients with H. pylori infection, (2) intervention-eradication therapy through the vonoprazan-based triple therapy, (3) comparator-eradication therapy through the PPI-based triple therapy, and (4) outcomeeradication rate, dropout rate and adverse event. The following study types were excluded: (1) animal studies, (2) abstract-only publications or unpublished studies and (3) publications in a language other than English. Two investigators (Y.S.J. and C.H.P.) independently evaluated the studies for eligibility; any disagreements were resolved through discussion and consensus. If no agreement could be reached, a third investigator (E.H.K.) determined eligibility.
To understand the risk of bias in each study, we carried out a formal quality assessment of the studies. 
| Statistical analysis
Meta-analyses were performed to calculate the pooled risk ratios (RRs) with a 95% confidence interval (CI). 31 A random-effects model was used, as this provides a more conservative estimate than a fixed effects model when heterogeneity is present.
We assessed heterogeneity using two methods: Cochrane's Q The full texts of the 11 remaining articles were reviewed, and one more non-pertinent article was excluded, which investigated the negative conversion rates of the urea breath test after administration of either PPI or vonoprazan without antibiotics. 38 Ultimately, 10 studies and 10 644 patients were deemed appropriate for inclusion in our systematic review and meta-analysis. 15, [19] [20] [21] [22] [23] [24] [25] [26] [27] The characteristics of the included studies are summarised in Table 1 . These studies had been published between 2016 and 2017, and their enrollment periods ranged from 2011 to 2016. All of the included studies were performed in Japan, and only one was an RCT. 19 The remaining nine were retrospective cohort studies. 15, [20] [21] [22] [23] [24] [25] [26] In five (55.6%) of the nine retrospective cohort studies, 15, 20, [23] [24] [25] group allocation (vonoprazan-based vs PPI-based) was performed according to the period of treatment, as vonoprazan was approved in 2015 in Japan. In other words, the PPI-based triple therapy and vonoprazan-based triple therapy were used before 2015 and after 2015, respectively, in the studies. In one retrospective cohort study, group allocation was performed according to the day of treatment. 26 The remaining three studies did not provide information regarding the group allocation methods. 21, 22, 27 Of the total included studies, three (one RCT and two retrospective studies) provided eradication rates according to the clarithromycin-susceptibility.
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Records identified through database searching (n = 122)
Additional records identified through other sources (manual searching) (n = 0)
Records after duplicates removed The one RCT was determined to have an unclear risk of allocation concealment; however, it showed a low risk of bias in the following other domains: sequence generation, blinding of participants, personnel and outcome assessors, incomplete outcome data, selective outcome reporting, and other sources of bias. 19 In addition, all eight retrospective cohort studies were considered to be of high 15, 20, [22] [23] [24] [25] [26] [27] which were conducted after 2013, included all patients with H. pylori infection (in both the PPI-based and vonoprazan-based therapy groups). In these studies, the non-exposed cohort (PPI-based triple therapy group) was considered as being drawn from the same community as the exposed cohort (vonoprazan-based triple therapy group). However, the remaining one retrospective study 21 included only patients with peptic ulcer or gastric tumour between 2011 and 2012 (only in the PPI-based triple therapy group), whereas all patients with H. pylori infection were included after 2013 (in both the PPI-based and vonoprazan-based triple therapy groups). In this study, therefore, the NOS score in the selection of the non-exposed cohort category was unassigned. Figure S1 ).
| Comparative efficacy of eradication therapy
In cases of PP analysis, six studies were included. 15 Figure S5 .
| DISCUSSION
The identification of optimal regimens in the treatment of H. pylori is challenging due to increasing resistance to antibiotics, particularly clarithromycin. The Maastricht V/Florence Consensus Report stated that PPI-clarithromycin-containing triple therapy without prior susceptibility testing should be abandoned in regions where the clarithromycin resistance rate is above 15%. 39 Nevertheless, the use of PPI-based triple therapy without susceptibility testing is common in many countries including Korea, Japan and China, because treatment based on the susceptibility test requires more time and higher costs compared to the empirical treatment. 40 Given this clinical reality, vonoprazan-based therapy may be an appropriate alternative treatment option for H. pylori infection. In our study, the vonoprazan-based triple therapy was shown to have a higher eradication rate compared to the PPI-based triple therapy (87.9% vs 72.8% respectively). According to the report card to grade H. pylori therapies, proposed by Graham, 41 the 72.8% eradication rate in the PPI-based triple therapy constitutes an unacceptable grade (grade F). On the contrary, the 87.9% eradication rate in the vonoprazan-based triple therapy is an acceptable grade (grade C).
Such superior efficacy of the vonoprazan-based triple therapy may be due to its potent acid-inhibitory effect. 17 Previously, a metaanalysis on H. pylori eradication comparing between high-dose and standard-dose PPI-based triple therapies showed that high-dose PPI That is a surprising result; however, a concern related to the clarithromycin-resistant strains remains. Although eradication rates could be improved with the use of vonoprazan, the eradication rate of the vonoprazan-based triple therapy did not reach an acceptable grade (≥85% by ITT analysis) according to the report card for grading H. pylori therapies. 41 Therefore, the vonoprazan-based triple therapy cannot be an ultimate solution for the treatment of clarithromycinresistant H. pylori. To overcome the insufficient eradication rate of the clarithromycin-resistant strains, susceptibility testing before treatment should be considered. 44 In addition, further studies are needed to evaluate whether other vonoprazan-based regimens (eg vonoprazan-based sequential therapy) achieve an acceptable eradication rate even in the context of clarithromycin-resistant strains.
Additional interesting findings of our meta-analysis were the low dropout rate (0.5%) and low incidence of adverse events ( If both regimens were used in the same period, the relative efficacy of the vonoprazan-based triple therapy might increase. Even though heterogeneity across studies is a limitation of our metaanalysis, the benefit of the vonoprazan-based triple therapy is unequivocal.
Although vonoprazan is a newly developed drug, its efficacy has been proven in various gastrointestinal diseases as well as H. pylori infection. [45] [46] [47] [48] Compared with PPI, vonoprazan showed comparable efficacy and tolerability in patients with erosive esophagitis and peptic ulcers. [45] [46] [47] Additionally, vonoprazan better decreased the risk of post-endoscopic submucosal dissection bleeding than did PPI. 48 We believe that vonoprazan is a promising drug in the treatment of diseases requiring acid inhibition.
Although our meta-analysis demonstrated the benefit of the vonoprazan-based triple therapy, it has several limitations. First, most of the included studies were designed as retrospective cohort studies, rather than as RCTs. The retrospective nature of the studies might induce heterogeneity across the included studies, as mentioned above. Second, all of the included studies were performed in Japan. Since antibiotic resistance varies depending on the country, our results may not be generalisable worldwide. Additionally, the usual dosage of antibiotics in the conventional triple therapy may differ depending on the country. Further studies should be conducted in a multitude of regions in order to reach a definitive conclusion. Third, alternative regimens other than the conventional triple therapy for 7 days were not considered in the meta-analysis.
Therefore, we could not evaluate whether vonoprazan-based regimens were superior to PPI-based regimens other than the 7-day triple therapy. Since the eradication rate of the vonoprazan- Despite these limitations, our meta-analysis provides a better understanding of the benefit of vonoprazan-based triple therapy.
The vonoprazan-based triple therapy showed superior efficacy to the PPI-based triple therapy in terms of H. pylori eradication. In addition, the vonoprazan-based triple therapy showed comparable tolerability and incidence of adverse events to those of the PPI-based triple therapy.
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